Newsletter

Subscribe to our newsletter to stay informed.

Newsletter Overlay EN
Salutation
* Mandatory fields
Policy
Member Login Interpharma Newsletter
Go to the Interpharma page
ENFRDE
Directory

Fighting Covid-19 together

1. Race against time
2. Pooling expertise and resources
3. Research into existing substances
4. Vaccine development in record time
5. Why animal experiments are necessary
6. Guaranteeing supply security
7. Excursus: People’s initiative “Yes to a ban on experiments in animals and humans – Yes to research avenues with impetus for safety and progress”

3. Research into existing substances

Further research into substances that are already known is an important pillar in the search for active substances. Hundreds of clinical trials are currently under way around the world, in which existing medicines are being studied for their efficacy against the SARS-CoV-2 virus. The member companies of Interpharma are also involved in this effort, for example in the testing of older antimalarial or HIV medicines. A major success has been achieved by Gilead: the medicine remdesivir, which was originally intended for the treatment of Ebola, is the first approved antiviral therapy that significantly reduces the recovery time in Covid-19 patients.

Next post